(HealthDay)—For patients with rheumatoid arthritis who have had an inadequate response to methotrexate, baricitinib is associated with significant clinical improvements, compared to either placebo or adalimumab, according ...
Feb 20, 2017
0
0
A clinical study co-led by the Montreal Heart Institute and Innovaderm Research Inc., which was presented today at the annual meeting of the American Academy of Dermatology, shows that a new treatment for psoriasis could ...
Mar 16, 2012
0
0
Patients with inflammatory rheumatic diseases (IRD) treated with anti-tumour necrosis factor medications (anti-TNFs) have a 75% greater risk of developing herpes zoster, or shingles, than patients treated with traditional ...
Jun 7, 2012
0
0
(HealthDay)—Doctors who treat patients with psoriasis show wide variation in their beliefs about the safety and effectiveness of psoriasis treatments, according to a study published in the February issue of the Journal ...
Feb 7, 2013
0
0
Data presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, demonstrates that tocilizumab monotherapy is more effective than adalimumab monotherapy in the treatment of rheumatoid arthritis ...
Jun 6, 2012
0
0
Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...
Oct 23, 2014
0
0
(HealthDay)—For patients with rheumatoid arthritis (RA), long-term clinical outcomes are good with etanercept and adalimumab; but for adalimumab, treatment response is strongly dependent on the presence or absence of anti-adalimumab ...
Dec 13, 2012
0
1
Adalimumab (an anti-tumor necrosis factor [TNF] antibody) is effective in maintaining remission in certain pediatric patients with Crohn's disease, according to a new study in Gastroenterology, the official journal of the ...
Aug 6, 2012
0
0
Data from one of the few head-to-head trials in rheumatoid arthritis (RA) presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, demonstrates that at one year, 64.8% of patients receiving ...
Jun 7, 2012
0
1
The results of two phase 3 clinical trials that led to FDA approval of adalimumab for treatment of the chronic inflammatory skin disease hidradenitis suppurtiva (HS) are being published in the August 4 New England Journal ...
Aug 3, 2016
0
4
